Abnormal Uterine Bleeding

Rating : Rate It:
drehsan shinwar    on Jan 02, 2013 Says :

very interesting and helpful
amani albasheer    on Nov 15, 2012 Says :

informative & concise topic
Hussein    on Oct 16, 2012 Says :

very good topic
kasireddy    on Aug 08, 2011 Says :

very useful ppt presentation
elsir    on May 16, 2010 Says :

nice topic
chanaka    on Apr 21, 2010 Says :

very important presantataion.easy to teach
Post a comment
    Post Comment on Twitter
18 Favorites
maysafarag,   favourited this   2 Years ago.
afshaneWe6,   favourited this   3 Years ago.
ashrafjosef,   favourited this   3 Years ago.
amir_rahbarfar1391,   favourited this   3 Years ago.
dr akl,   favourited this   3 Years ago.
mabr4_bam,   favourited this   3 Years ago.
hananahmed63,   favourited this   3 Years ago.
anshukabra02,   favourited this   3 Years ago.
mbmerbenz2,   favourited this   3 Years ago.
First Prev [1] 2 Next Last

1 : Abnormal Uterine Bleeding Lloyd Holm, D.O., FACOG Associate Professor Department of Obstetrics and Gynecology University of Nebraska Medical Center
2 : Abnormal Uterine Bleeding Definitions Etiologies Evaluation and workup Case presentation Management and options
3 : Definitions Normal: Mean interval is 28 days +/- 7 days. Mean duration is 4 days. More than 7 days is abnormal.
4 : Average blood loss with menstruation is 35-50cc. 95% of women lose <60cc.
5 : Definitions Menorrhagia: Prolonged > 7 days or > 80 cc occurring at regular intervals. Synonymous with hypermenorrhea
6 : Menorrhagia occurs in 9-14% of healthy women.
7 : Definitions Metrorrhagia: Uterine bleeding occurring at irregular but frequent intervals.
8 : Definitions Menometrorrhagia: Prolonged uterine bleeding occurring at irregular intervals.
9 : Definitions Oligomenorrhea: Infrequent uterine bleeding varying between 35 days and 6 months.
10 : Definitions Amenorrhea: No menses for 6 months.
11 : 40% of women with blood loss >80cc considered their flow to be small or moderate. 14% of women with <20cc loss thought their flow was heavy. Hallberg, et al., 1966
12 : One third of light menses were actually >80cc and one-half of those believed to be heavy were <80cc. Chimbira, et al., 1980
13 :
14 : Etiologies Organic Systemic Reproductive tract disease Iatrogenic Dysfunctional Ovulatory Anovulatory
15 : Systemic Etiologies Coagulation defects Leukemia ITP Thyroid dysfunction
16 : In a 9 year review of 59 cases of acute menorrhagia in adolescents it was discovered that 20% had a primary coagulation disorder. Claessens, et al., 1981
17 : Routine screening for coagulation defects should be reserved for the young patient who has heavy flow with the onset of menstruation. Comprehensive Gynecology, 4th edition
18 : von Willebrand’s Disease is the most common inherited bleeding disorder with a frequency of 1/800-1000. Harrison’s Principles of Internal Medicine, 14th edition
19 : Hypothyroidism can be associated with menorrhagia or metrorrhagia. The incidence has been reported to be 0.3-2.5%. Wilansky, et al., 1989
20 : Most Common Causes of Reproductive Tract AUB Pre-menarchal Foreign body Reproductive age Gestational event Post-menopausal Atrophy
21 : Reproductive Tract Causes Gestational events Malignancies Benign Atrophy Leiomyoma Polyps Cervical lesions Foreign body Infections
22 : Reproductive Tract Causes Gestational events Abortions Ectopic pregnancies Trophoblastic disease IUP
23 : Reproductive Tract Causes Malignancies Endometrial Ovarian Cervical
24 : 10% of women with postmenopausal bleeding will be diagnosed with endometrial cancer and an equal number with hyperplasia. Karlsson, et al., 1995
25 : Incidence of Endometrial Cancer in Premenopausal Women 2.3/100,000 in 30-34 yr old 6.1/100,000 in 35-39 yr old 36/100,000 in 40-49 yr old ACOG Practice Bulletin #14, 2000
26 : Reproductive Tract Causes of Benign Origin Atrophy Leiomyoma Polyps Cervical lesions Foreign body Infection
27 : 60% of women with PMB will be found to have atrophy. 10% will have polyps and 10% will have hyperplasia. Karlsson, et al., 1995
28 : Proposed Etiologies of Menorrhagia with Leiomyoma Increased vessel number Increased endometrial surface area Impeded uterine contraction with menstruation Clotting less efficient locally Wegienka, et al., 2003
29 : Leiomyoma in any location is associated with increased risks of gushing or high pad/tampon use. Wegienka, et al., 2003
30 : Iatrogenic Causes of AUB Intra-uterine device Oral and injectable steroids Psychotropic drugs
31 : DUB Abnormal uterine bleeding for which an organic etiology has been excluded. It is either ovulatory or anovulatory in origin.
32 : To determine if DUB is ovulatory or anovulatory…. History Daily basal body temperature Luteal phase progesterone Luteal phase EMB
33 : The majority of dysfunctional AUB in the premenopausal woman is a result of anovulation. Comprehensive Gynecology, 4th edition
34 : With anovulation a corpus luteum is NOT produced and the ovary thereby fails to secrete progesterone.
35 : However, estrogen production continues, resulting in endometrial proliferation and subsequent AUB.
36 : PGE2 ? vasodilation PGF2a ? vasoconstriction Progesterone is necessary to increase arachidonic acid, the precursor to PGF2a. With decreased progesterone there is a decreased PGF2a/PGE2 ratio.
37 : Since vasoconstriction is promoted by PGF2a, which is less abundant due to the decrease in progesterone, vasodilation results thereby promoting AUB.
38 :
39 : Evaluation and Work-up: Early Reproductive Years/Adolescent Thorough history Screen for eating disorder Labs: CBC, PT, PTT, bleeding time, hCG
40 : One should consider an EMB for adolescents with 2-3 year history of untreated anovulatory bleeding in obese females < 20 years of age. ACOG Practice Bulletin #14, March 2000
41 : Evaluation and Work-up: Women of Reproductive Age hCG, LH/FSH, CBC Cervical cultures U/S Hysteroscopy EMB
42 : Evaluation and Work-up: Post-menopausal Women FSH/LH? Transvaginal U/S EMB Hysteroscopy with endometrial sampling???
43 : An endometrial cancer is diagnosed in approximately 10% of women with PMB.¹ PMB incurs a 64-fold increased risk for developing endometrial CA.² ¹Karlsson, et al., 1995 ²Gull, et al., 2003
44 : Not a single case of endometrial CA was missed when a <4mm cut-off for the endometrial stripe was used in their 10 yr follow-up study. Specificity 60%, PPV 25%, NPV 100% Gull, et al., 2003
45 : There was no increased risk of endometrial cancer or atypia in those women who did not experience recurrent PMB in their 10 year follow-up. Gull, et al., 2003
46 : Further, no endometrial cancer was diagnosed in women with recurrent PMB who had an endometrial stripe width of <4mm on their initial scan. Gull, et al., 2003
47 : Nevertheless, there is a 7.1% risk of endometrial atypia in those women with a stripe width less than or equal to 4mm and recurrent bleeding. Gull, et al., 2003
48 : However, 3 women with stripe width of 5-6mm developed recurrent PMB and were diagnosed with endometrial cancer within 3-5 years. Gull, et al., 2003
49 : The stripe thickness measures between 4-8mm in women on cyclic HRT and about 5mm if they are receiving combined HRT. Good, 1997
50 : EMB Complications rare. Rate of perforation 1-2/1,000. Infection and bleeding rarer. Comprehensive Gynecology, 4th ed.
51 : EMB Sensitivity 90-95% Easy to perform Numerous sampling devices available
52 : Incidence of Endometrial Cancer in Premenopausal Women 2.3/100,000 in 30-34 yr old 6.1/100,000 in 35-39 yr old 36/100,000 in 40-49 yr old ACOG Practice Bulletin #14, 2000
53 : Therefore, based upon age alone, an EMB to exclude malignancy is indicated in any woman > 35 years of age with AUB. ACOG Practice Bulletin #14, March 2000
54 : Endometrial Cancer Most common genital tract malignancy. Incidence 1 in 50! 4th most common malignancy after breast, bowel, and lung. 34,000 new cases annually > 6,000 deaths annually
55 : Endometrial Cancer Risk Factors Nulliparity: 2-3 times Diabetes: 2.8 times Unopposed estrogen: 4-8 times Weight gain 20 to 50 pounds: 3 times Greater than 50 lbs: 10 times!
56 : Possible Path Reports with EMB: Proliferative, secretory, benign, or atrophic endometrium Inactive endometrium Tissue insufficient for evaluation No endometrium seen
57 : Possible Path Reports with EMB: Simple or complex hyperplasia WITHOUT atypia Simple or complex hyperplasia WITH atypia Endometrial cancer
58 : Hysteroscopy Previously considered the “gold standard” Advantage of intervention at time of diagnosis Recent reports demonstrating positive peritoneal cytology in endometrial cancer patients who undergo hysteroscopy
59 : Hysteroscopy 256 patients with endometrial cancer 204 diagnosed by EMB or D&C and 52 diagnosed by hysteroscopy In the EMB/D&C arm, 6.9% had + cytology In the hysteroscopy arm, 13.5% had + cytology p = 0.03 Bradley, et al., 2004
60 : Management Prior to initiation of therapy: pregnancy and malignancy must be ruled out.
61 :
62 : Management Options: Progestins Estrogen OCs NSAIDs Antifibrinolytics Surgical
63 : Progestins: Mechanisms of Action Inhibit endometrial growth Inhibit synthesis of estrogen receptors Promote conversion of estradiol ? estrone Inhibit LH Organized slough to basalis layer Stimulate arachidonic acid formation
64 : Management: Progesterone Cyclooxygenase Pathway Arachidonic Acid Prostaglandins PGF2a* Thromboxane Prostacyclin *Net result is increased PGF2a/PGE ratio
65 : Adolescent anovulatory patients are ideally suited for progestins as the development of the immature hypothalamic-pituitary axis is not impeded.
66 : Progestins are the preferred treatment for those women with anovulatory AUB. Cyclic progesterone is not recommended for ovulatory AUB.
67 : Progestational Agents Cyclic medroxyprogesterone 2.5-10mg daily for 10-14 days Continuous medroxyprogesterone 2.5-5mg daily Progesterone in oil, 100mg every 4 weeks DepoProvera® 150mg IM every 3 months Levonorgestrel IUD (5 years)
68 : Consider a progestational IUD as a viable option in the management of anovulatory/ovulatory AUB. Induced endometrial atrophy for more than 5 years.
69 : Levonorgestrel-releasing Intrauterine System Study to evaluate LNG-IUS in women with menorrhagia Retrospective review 68% (n=28) experienced improvement with LNG-IUS Authors recommend serious consideration Schaedel, et.al. Am J Obstet Gynecol 2005;193:1361
70 : Treatment of menorrhagia with IUD vs endometrial resection Randomized 3 year trial, total N=59 Levonorgestrel IUD or resection group High continuation rate with IUD group Blood loss reduction similar in both groups Rauramo I, et al. Obstet Gynecol 2004;104:1314
71 : Endometrial Hyperplasia It is reasonable for you to initiate a progestational agent if an EMB path report indicates simple hypersplasia WITHOUT atypia. Provera® 5-10 mg daily with a f/u plan for an EMB in 6 months. Referral is prudent if bleeding persists or worsens.
72 : Management: Estrogen Conjugated estrogens given IV in 25mg doses every 6 hours should be effective in controlling heavy bleeding. This is followed by PO estrogen.
73 : Management: Estrogen For less severe bleeding, PO Premarin® 1.25mg, 2 tabs QID until bleeding ceases.
74 : Management: NSAIDs Cyclooxygenase Pathway Arachidonic Acid Prostaglandins Thromboxane Prostacyclin* ?cyclic endoperoxides are inhibited, therefore this step is blocked X *Causes vasodilation and inhibits platelet aggregation
75 : Antifibrinolytics: Tranexamic Acid Cyklokapron® Used extensively in Europe Mainstay of treatment of ovulatory AUB in most of the world Reduces blood loss by 45-50% Non-FDA labeled indication
76 : Surgical Options: Laser ablation Thermal ablation Resection Hysterectomy
77 : Comparison of Ablative Techniques Amenorrhea Satisfaction Laser/resection 45%¹ 90%¹ Thermal ablation 15%² 90%² ¹Aberdeen Trial Group, 1999 ²Meyer et al., 1998
78 : Case Presentation Pt is a 45 y/o female who presented with a hx of post-menopausal bleeding. She was treated from breast cancer in 2004 with CT and RT. ER neg and PR pos. No tamoxifen. Subsequent to treatment she was menopausal. In 2006 she began having vaginal bleeding.
79 : Evaluation U/S
80 : Evaluation U/S Labs
81 : Evaluation U/S Labs EMB
82 : Evaluation U/S “cystic endometrium, likely secondary to tamoxifen therapy.” Endometrial stripe at 11 mms.
83 : Evaluation Labs FSH 15 TSH 1.2
84 : Evaluation EMB Secretory endometrium No evidence of hyperplasia or malignancy
85 : Diagnosis?
86 : Summary Think coagulation defect in the menarchal adolescent patient with severe menorrhagia Gestational events are the single most likely cause of AUB in reproductive age women 35 yrs and older with AUB ? EMB If Rx estrogen be sure to screen for contraindications Levonorgestrel IUD is excellent means to control AUB
87 : Summary Most common cause of AUB in post-menopausal women is atrophy TVS is an excellent screening tool for the evaluation of PMB Women with recurrent PMB require definitive F/U Endometrial CA risk factors: age, obesity, unopposed estrogen, DM, and ?BP Recents reports have demonstrated “upstaging” with hysteroscopy and endometrial CA pts.
88 :


Add as Friend By :
Added On : 7 Years ago.
Department of Obstetrics and Gynecology. University of Nebraska Medical Center. Abnormal Uterine Bl    more
Views 15983 | Favourite 19 | Total Upload :628023

Embed Code:

Flag as inappropriate

Related  Most Viewed

Free Powerpoint Templates


Medical PowerPoint Templates | Powerpoint Templates | Tags | Contact | About Us | Privacy | FAQ | Blog

© Slideworld